Structure Therapeutics (GPCR) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 6.1% versus a loss of 24.3%. Structure Therapeutics is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | SRPT |
|---|---|---|
| Share price | $26.68 | $17.50 |
| Market cap | $1.90B | $1.85B |
| 1-day change | -2.88% | +1.10% |
| YTD return | -61.64% | -18.68% |
| 1-year return | -6.12% | -24.31% |
| 5-year return | — | -79.21% |
| Forward P/E | — | 7.26 |
| EPS (TTM) | $-2.94 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $94.90 | $24.68 |
| 52-week low | $25.59 | $14.68 |
| Distance from 52-week high | -71.89% | -29.09% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +296.48% | +24.17% |
| Average volume | 956.06K | 2.99M |
| Shares outstanding | 71.31M | 105.63M |
| Employees | 281 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed SRPT by 18.2 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
GPCR vs SRPT FAQ
Which is bigger, Structure Therapeutics or Sarepta Therapeutics?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.90B compared with $1.85B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, GPCR or SRPT?
GPCR returned -6.12% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.